ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bisphosphonates"

  • Abstract Number: 1149 • ACR Convergence 2021

    Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis

    Saffa Iftikhar1, Waleed Khokher2, Ashu Acharya1, Joan Gekonde3, Nithin Kesireddy2, Rawish Fatima1 and Nezam Altorok2, 1University of Toledo Medical Center, Toledo, OH, 2University of Toledo, Toledo, OH, 3University of Toledo, Sylvania Township, OH

    Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
  • Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting

    Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study

    David Kendler1, Arkadi Chines 2, Patricia Clark 3, Peter R. Ebeling 4, Michael McClung 5, Yumie Rhee 6, Shuang Huang 2, Robert Kees Stad 7 and Nick Freemantle 8, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, 4Monash University, Melbourne, Victoria, Australia, 5Oregon Osteoporosis Center, Portland, OR, 6Yonsei University College of Medicine, Seoul, Republic of Korea, 7Amgen Inc., Rotkreuz, Zug, Switzerland, 8University College London, London, England, United Kingdom

    Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
  • Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting

    The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study

    Salman Mahmood1, Yuanyuan Ji 2, Yi Peng 2 and Zaki Abou Zahr 1, 1Hennepin Healthcare, Minneapolis, MN, 2Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN

    Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
  • Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting

    T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial

    Felicia Cosman1, E. Michael Lewiecki2, Peter R Ebeling3, Eric Hesse4, Nicola Napoli5, Daria B Crittenden6, Maria Rojeski6, Wenjing Yang6, Cesar Libanati7 and Serge Ferrari8, 1Columbia University, New York, NY, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 3Monash University, Melbourne, Australia, 4University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 5Campus Bio-Medico University of Rome, Rome, Italy, 6Amgen Inc., Thousand Oaks, CA, 7UCB Pharma, Brussels, Belgium, 8Geneva University Hospital, Geneva, Switzerland

    Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
  • Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting

    Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture

    Mariana O Perez1, Diogo S Domiciano1, Luciene M Reis2, Vanda Jorgetti2 and Rosa M R Pereira1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 2Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
  • Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting

    Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays

    Jeffrey R. Curtis1, Rui Chen1, Tarun Arora1, Shanette Daigle1, Robert Matthews1, Huifeng Yun1, Nicole Wright2, Ayesha Jaleel3, Elizabeth Delzell4 and Kenneth Saag5, 1University of Alabama at Birmingham, Birmingham, AL, 2Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmngham, AL, 4Retired - University of Alabama at Birmingham, Birmingham, AL, 5UAB, Birmingham, AL

    Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
  • Abstract Number: 1256 • 2018 ACR/ARHP Annual Meeting

    A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors

    Shardool Patel1, Zachary L. Anderson1, Grant W. Cannon2, Brian C. Sauer2 and Karla L. Miller2, 1Salt Lake City VA Medical Center, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose: Osteoporosis is underdiagnosed and undertreated in the Veterans Health Administration (VHA), especially in rural Veterans. Tools to identify risk factors in Veterans are available.…
  • Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting

    Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study

    Kenneth Saag1, Nicola Pannacciulli2, Piet Geusens3, Jonathan D. Adachi4, Osvaldo D. Messina5, Jorge Morales-Torres6, Ronald Emkey7, Peter W. Butler2, Xiang Yin2 and Willem F. Lems8, 1University of Alabama at Birmingham, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5Cosme Argerich Hospital, Buenos Aries, Argentina, 6Hospital Aranda de la Parra, Leon, Mexico, 7Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, 8VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
  • Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting

    Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals

    Kenneth Saag1, Nicola Pannacciulli2, Piet Geusens3, Jonathan D. Adachi4, Eric Lespessailles5, Jorge Malouf6, Bente Langdahl7, Peter W. Butler2, Xiang Yin2 and Willem F. Lems8, 1University of Alabama, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5University Hospital Orleans, Orleans, France, 6Hospital San Pablo, Barcelona, Spain, 7Aarhus University, Aarhus, Denmark, 8VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
  • Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting

    Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality

    Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland

    Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
  • Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting

    Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial

    Cristiano A.F Zerbini1, Piet Geusens2, Eric Lespessailles3, Jean-Jacques Body4, Enrique Casado5, Jan Stepan6, David L Kendler7, Luis Russo8, Susan L. Greenspan9, Salvatore Minisola10, Alicia Bagur11, Peter Lakatos12, Astrid Fahrleitner-Pammer13, Rüdiger Möricke14, Pedro Lopez-Romero15 and Fernando Marin16, 1Centro Paulista de Investigações Clinicas, São Paulo, Brazil, 2Maastricht University Hospital, Maastricht, Netherlands, 3Service de Rhumatologie, CHR d'Orléans, Orléans, France, 4CHU Brugmann, Free University Brussels, Brussels, Belgium, 5Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, 6Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic, 7University of British Columbia, Vancouver, BC, Canada, 8Centro de Analises e Pesquisas Clínicas LTDA,, Rio de Janeiro, Brazil, 9University of Pittsburgh, Pittsburgh, PA, 10Internal Medicine, Policlinico Umberto I,, Rome, Italy, 11Centro de Osteopatías Comlit, Buenos Aires, Argentina, 12Department of Medicine, Semmelweis University, Budapest, Hungary, 13Division of Endocrinology, Medical University, Graz, Austria, 14Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany, 15Europe Research Center, Eli Lilly and Company, Madrid, Spain, 16Lilly Research Center Europe, Madrid, Spain

    Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…
  • Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting

    A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates

    Paul D Miller1, N Pannacciulli2, J Malouf3, A Singer4, E Czerwinski5, HG Bone6, C Wang2, Rachel B. Wagman2 and JP Brown7, 1Colorado Center for Bone Research, Lakewood, CO, 2Amgen Inc., Thousand Oaks, CA, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Georgetown University Medical Center, Washington, DC, 5Krakow Medical Center, Krakow, Poland, 6Michigan Bone and Mineral Clinic, Detroit, MI, 7CHU de Québec Research Centre and Laval University, Québec, QC, Canada

    Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…
  • Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting

    Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis

    Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan

    Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…
  • Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting

    Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data

    Mariana O Perez1, Diogo S Domiciano1, Vanda Jorgetti2 and Rosa M R Pereira1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 2Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
  • Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting

    The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates

    Jeffrey R. Curtis1, Rui Chen2, Zixu (Eric) Li2, Tarun Arora2, Kenneth Saag3, Nicole C. Wright4, Shanette Daigle2, Meredith Kilgore5 and Elizabeth Delzell6, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, 4Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, 6Retired - University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology